Clinical Trial

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Study acronym: Ametrine-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-06-30 -> 2027-01-30 2026-04-03
minor Completion pushed: 2029-12-30 -> 2031-01-30 2026-04-03
Trial Details
NCT Number NCT06588855
Lead Sponsor Hoffmann-La Roche
Conditions Moderately to Severely Active Ulcerative Colitis
Enrollment 350 participants
Start Date 2024-12-11
Primary Completion 2027-01-30 (estimated)
Study Completion 2031-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02